GlassScriptPhysician profile
William L Lombardi
NPI 1942250717
$901,687.23
in general payments reported to CMS, 2019-2025
28 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368K · 2020: $85K · 2021: $84K · 2022: $133K · 2023: $167K · 2024: $54K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $164K · Travel and Lodging: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $13K · Food and Beverage: $11K · Honoraria: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $164,268.11 |
| Travel and Lodging | $25,420.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,475.00 |
| Consulting Fee | $12,825.00 |
| Food and Beverage | $11,352.36 |
| Honoraria | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asahi Intecc Co., LTD. | $274,229.70 | 2019-2025 | Asahi Ptca Guide Wire Asahi Gladius Mongo 14, Peripheral Vascular |
| Corindus INC. | $238,548.86 | 2019 | |
| Asahi Intecc USA, INC. | $149,631.75 | 2019-2025 | Asahi Coronary Wires, Asahi Interventional Radiology Wires, Asahi Gladius Mongo14 Es |
| Boston Scientific Corporation | $94,696.32 | 2019-2025 | General - Vascular Access, General - Therapies, Avvigo Guidance System |
| Medtronic, INC. | $31,339.26 | 2021-2024 | Resolute Onyx, Onyx Frontier, Symplicity G3 |
| Reflow Medical INC | $23,484.23 | 2023-2025 | |
| Medtronic Vascular, INC. | $21,862.05 | 2019-2020 | |
| Siemens Medical Solutions USA, INC. | $15,731.56 | 2019-2022 | |
| Abbott Laboratories | $14,576.66 | 2019-2025 | Pressurewire, Xience Sierra, Xience Skypoint |
| Vascular Solutions, INC. | $12,440.21 | 2019 | |
| Abiomed | $7,622.88 | 2019-2025 | Impella |
| Teleflex LLC | $5,018.83 | 2019-2025 | Guideliner, Supercross, Turnpike |
| Philips North America LLC | $4,212.53 | 2019-2023 | |
| Shockwave Medical, INC | $2,704.58 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,000.00 | 2024-2025 | Lifevest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arrow International, INC. | $1,272.94 | 2020-2024 | Guideliner |
| Biosense Webster, INC. | $725.00 | 2023 | Carto 3 |
| Biotronik INC. | $674.95 | 2019-2023 | Orsiro Mission |
| Celonova Biosciences, INC. | $213.30 | 2019 | |
| Edwards Lifesciences Corporation | $201.65 | 2024 | |
| W. L. Gore & Associates, INC. | $123.41 | 2025 | Gore Cardioform Septal Occluder |
| Chiesi USA, INC. | $107.24 | 2023 | |
| Avinger INC. | $101.92 | 2019 | |
| Spectrawave, INC | $79.64 | 2023-2025 | Hypervue Imaging System, Starlight Imaging Catheter |
| Verge Medical, INC. | $49.54 | 2025 | Ostial Flash System |
| Heartflow, INC. | $34.03 | 2019 | |
| Cardiovascular Systems INC. | $4.19 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,209,499.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lombardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.